Stocks in play: BioVaxys Technology Corp
Along with SpayVac-for-Wildlife, Inc. jointly announce that SpayVac has partnered with a world leader in the aquaculture space to field test single-injection, long-lasting immuno-contraceptive vaccines in the commercial aquatic farming industry, specifically in farmed rainbow trout. SpayVac utilizes a patented liposome-based antigen delivery platform technology licensed from BioVaxys and has demonstrated a robust and sustained immune response in several species. BioVaxys Technology Corp shares C.BIOV are trading up one cent at $0.08.
Read:
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Harnessing AI's $4.4 Trillion Potential Reshapes the Tech Industry Landscape
Critical Push for US Domestic Nickel Needed to Halt Total Reliance on Questionable Foreign Imports
How Argentina’s New Power Moves Look to Lure Even More Lithium Interest Towards the Country
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer